Relmada Therapeutics 경영진
경영진 기준 점검 2/4
Relmada Therapeutics CEO는 Sergio Traversa, Apr2012 에 임명되었습니다 의 임기는 14.08 년입니다. 총 연간 보상은 $8.89M, 8.9% 급여 및 91.1% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $9.14M 가치에 해당하는 회사 주식의 1.24% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 6.3 년과 6.4 년입니다.
핵심 정보
Sergio Traversa
최고경영자
US$8.9m
총 보수
| CEO 급여 비율 | 8.86% |
| CEO 재임 기간 | 14.1yrs |
| CEO 지분 보유율 | 1.2% |
| 경영진 평균 재임 기간 | 6.3yrs |
| 이사회 평균 재임 기간 | 6.4yrs |
최근 경영진 업데이트
Recent updates
새로운 내러티브 • May 16
Bladder Cancer Catalyst Faces Clinical And Patent Hurdles Yet Future Potential Remains
Catalysts About Relmada Therapeutics Relmada Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for non muscle invasive bladder cancer and compulsivity related neuropsychiatric disorders. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Mar 20
Phase III Bladder Cancer Catalyst Will Drive Long Term Value For This Biotech
Catalysts About Relmada Therapeutics Relmada Therapeutics is a clinical stage biopharmaceutical company focused on developing NDV-01 for non muscle invasive bladder cancer and sepranolone for compulsivity related neurological disorders. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Mar 05
Bladder Cancer And Compulsive Disorder Therapies Will Support A Stronger Long Term Outlook
Catalysts About Relmada Therapeutics Relmada Therapeutics is a clinical stage biopharmaceutical company developing NDV-01 for non muscle invasive bladder cancer and sepranolone for compulsive behavior disorders such as Prader Willi syndrome. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Mar 21
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
Summary RLMD plans to report results from the phase 3 Reliance II study of REL-1017, as an adjunctive treatment for major depressive disorder, in H2 2024. The current timeline for completion of enrolment in Reliance II may suggest a slight slippage, but my position on the potential for a run up is unchanged. RLMD notes it has cash to complete its current studies Reliance II and Relight, as well as a phase 1 study of modified release psilocybin. Read the full article on Seeking Alpha분석 기사 • Mar 13
Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Jan 14
Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark
Summary Relmada Therapeutics is developing REL-1017, a therapy for CNS diseases that targets hyperactive GluN2D channels in NMDA receptors. Phase 2 trial showed a rapid and sustained antidepressant effect in patients who did not respond to standard antidepressants. Phase 3 trial missed its primary endpoint, but post-hoc analysis showed a robust difference between REL-1017 and placebo when excluding certain clinical sites. Read the full article on Seeking Alpha분석 기사 • Dec 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...분석 기사 • Aug 29
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...분석 기사 • May 07
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Dec 15
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Oct 14
Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure
Truist and Guggenheim have downgraded Relmada Therapeutics (NASDAQ:RLMD) to hold and neutral, respecitvely, following the failure of phase 3 depression REL-1017. Truist lowered its price target to $10 from $90 (~54% upside based on Thursday's close) while Guggenheim doesn't have a target. Truist analyst Joon Lee wrote that based on conversations with key opinion leaders, REL-1017 would have faced headwinds on approval due to a REMS requirement and DEA scheduling. Guggenheim is removing its sales estimated for REL-1017. Analyst Yatin Suneja wrote that Relmada could still salvage the candidate by either adding substantially more participants to the RELIANCE 1 trial or persuade regulators to exclude patients from the handful of sites where a high placebo effect was observed. However, Suneja conceded the second option is less likely. Seeking Alpha's Quant Rating views Relmada (RLMD) as a hold with high marks for momentum and growth.Seeking Alpha • Sep 14
Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up
Summary We initiate Relmada Therapeutics with a Strong BUY rating due to our high degree of conviction on REL-1017's clinical success during the phase 3 trial. The phase 2 data showed that REL-1017 is rapid, effective, safe, and durable. Looking at the robust mechanism of action and phase 2 clinical data, we believe the clinical data to hold in phase 3. The key catalyst is REL-1017's phase 3 data that is expected in Q4 22 which we believe will move the stock price substantially and we are planning to start establishing a small option-sized position of the ticker. Background Relmada Therapeutics (NASDAQ:RLMD) is a US-based, pre-commercial stage biotech developing therapies for depressive disorders. The company is trading at a 700M enterprise value and holds 200M cash, which is a highly robust cash runway for a clinical-stage company. Accordingly, we initiate RLMD with a strong BUY rating. RLMD IR deck (RLMD IR deck) The unique mechanism of action of REL-1017 is key for best-in-class efficacy and safety REL-1017 is a novel first-in-class compound formulation of oral dextromethadone currently being studied to target depressive disease. We highlight that REL-1017 is the only compound that uniquely targets NMDA receptors to treat depression. The drug's key compositions are dextromethadone, the purified "d" enantiomer of methadone. We note that this is important for the drug's exceptional safety, a racemic mixture of "d" and "l" methadone is currently used to treat patients with opioid addiction problems; however, the "d" form lacks substantial opioid receptor activity and instead works as an NMDA receptor antagonist and channel blocker, similar to ketamine. Phase 2 efficacy and safety data points were effective and clean, we are optimistic about the success of the drug in phase 3 We highlight the key takeaways from phase 2 trials i) effective and durable anti-depressant effects on all tested scales, ii) rapid onset of action, with detected efficacy by day 4, iii) robust safety without opioid-related adverse events, psychotomimetic adverse events, and metabolic side-effects were shown, and iv) convenience - the drug is orally administered with a QD tablet formulation. RLMD IR deck (RLMD IR deck) Key findings are: Subjects in both the REL-1017 25 mg and 50 mg treatment groups experienced statistically significant improvement of their depression compared to subjects in the placebo group on all efficacy measures, including: the MADRS; the Clinical Global Impression – Severity (CGI-S) scale; the Clinical Global Impression – Improvement (CGI-I) scale; and the Symptoms of Depression Questionnaire (SDQ). The improvement on the MADRS appeared on Day 4 in both REL-1017 dose groups and continued through Day 7 and Day 14, seven days after treatment discontinuation, with p-values <0.03 and large effect sizes (a measure of quantifying the difference between two groups), ranging from 0.7 to 1.0. Similar findings emerged from the CGI-S and CGI-I scales. Source: company IR deck We believe REL-1017's remarkable potency combined with the drug's rapid and sustained effects make it the best-in-class agent currently being developed. We highlight that REL-1017 demonstrated impressive separation from placebo on the MADRS endpoint on Day 14. In comparison to SOCs, the ~9.4–10.4 reduction compared to placebo is more than double the reduction seen with approved anti-depressants. This level of efficacy was achieved in a more challenging, treatment-refractory patient population, which is highly promising moving forward in terms of commercial potential. Keeping the difference in study design in mind, if we compare REL-1017 to fellow NMDA receptor antagonists, Spravato, Spravato only demonstrated a 4.0 reduction in MADRS score over placebo at day 28 in its pivotal TRANSFORM-2 trial. RLMD IR deck (RLMD IR deck) RLMD IR deck (RLMD IR deck) as shown above (REL-1017 phase 2 study safety data (Company IR) No serious treatment-emergent adverse events were shown. In terms of safety, the global safety profile seems superior to Spravato as there were no reported dissociative/psychomimetic effects. Furthermore, there were no signs of opioid withdrawal upon treatment discontinuation. The most common adverse events included mild to moderate headache, nausea, and sedation, which were evenly distributed across the treatment arms, which does not concern us, and we believe the drug has a robust profile with a favorable risk/benefit as an MDD therapeutic candidate. Furthermore, we believe REL-1017's oral formulation to be more convenient for patients than Spravato's intranasal administration as it is less discrete. We believe the phase 3 trial design is robust and the endpoints are achievable for the drug based on their robust phase 2 performanceSeeking Alpha • Aug 09
Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression
Relmada Therapeutics (NASDAQ:RLMD) said on Tuesday the U.S. Food and Drug Administration had granted Fast Track designation to its drug, REL-1017, as a monotherapy to treat major depressive disorder. (RLMD) rose 3.3% premarket. For a fast track drug, the company must show some advantage over current therapy, such as superior effectiveness, effect on serious outcomes or improved effect on serious outcomes, and avoiding serious side effects of an available therapy. A drug that receives Fast Track designation is eligible for Accelerated Approval and Priority Review.분석 기사 • Jul 14
We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Feb 26
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Jan 28
4 Clinical Catalysts On Tap For Relmada In 2022
RLMD is set to produce results in 2022 from four clinical trials of REL-1017, its novel antidepressant. Late-stage failures of antidepressants are not unheard of, so I provide a cautionary tale to RLMD longs. The timing of readouts allows for an interesting potential trade, avoiding exposure to an earlier study which I feel has more downside than upside potential.분석 기사 • Nov 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Seeking Alpha • Jun 28
Our First Look At Relmada Therapeutics
Relmada Therapeutics, Inc.’s (RLMD) sole clinical asset, oral antidepressant therapy esmethadone, is undergoing two pivotal trials for the treatment of MDD. Phase 2 study data demonstrate a rapid onset of action that no other currently approved oral therapy can boast. Despite esmethadone’s promise, Axsome Therapeutics (AXSM) has a similar oral candidate (AXS-05) with a novel MOA and August 22nd, 2021 PDUFA date, suggesting an ~18-month head start. A full investment analysis is presented in the paragraphs below.분석 기사 • Jun 28
We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Mar 09
Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Jan 15
What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?
If you want to know who really controls Relmada Therapeutics, Inc. ( NASDAQ:RLMD ), then you'll have to look at the...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$59m |
| Dec 31 2025 | US$9m | US$788k | -US$57m |
| Sep 30 2025 | n/a | n/a | -US$56m |
| Jun 30 2025 | n/a | n/a | -US$68m |
| Mar 31 2025 | n/a | n/a | -US$76m |
| Dec 31 2024 | US$2m | US$751k | -US$80m |
| Sep 30 2024 | n/a | n/a | -US$86m |
| Jun 30 2024 | n/a | n/a | -US$87m |
| Mar 31 2024 | n/a | n/a | -US$94m |
| Dec 31 2023 | US$2m | US$701k | -US$99m |
| Sep 30 2023 | n/a | n/a | -US$112m |
| Jun 30 2023 | n/a | n/a | -US$129m |
| Mar 31 2023 | n/a | n/a | -US$144m |
| Dec 31 2022 | US$3m | US$668k | -US$157m |
| Sep 30 2022 | n/a | n/a | -US$153m |
| Jun 30 2022 | n/a | n/a | -US$157m |
| Mar 31 2022 | n/a | n/a | -US$143m |
| Dec 31 2021 | US$36m | US$630k | -US$126m |
| Sep 30 2021 | n/a | n/a | -US$112m |
| Jun 30 2021 | n/a | n/a | -US$86m |
| Mar 31 2021 | n/a | n/a | -US$71m |
| Dec 31 2020 | US$900k | US$600k | -US$59m |
| Sep 30 2020 | n/a | n/a | -US$43m |
| Jun 30 2020 | n/a | n/a | -US$30m |
| Mar 31 2020 | n/a | n/a | -US$23m |
| Dec 31 2019 | US$16m | US$214k | -US$15m |
보상 대 시장: Sergio의 총 보수(USD8.89M)는 US 시장에서 비슷한 규모 기업의 평균(USD3.79M)보다 높습니다.
보상과 수익: Sergio의 보상은 회사가 적자임에도 증가했습니다.
CEO
Sergio Traversa (65 yo)
14.1yrs
재임 기간
US$8,892,633
보수
Dr. Sergio Traversa, Pharm D., M.B.A. has been the Chief Executive Officer and a Director of Relmada Therapeutics, Inc. since April 18, 2012. Dr. Traversa served as Interim Chief Financial Officer at Relma...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | 14.1yrs | US$8.89m | 1.24% $ 9.1m | |
| Chief Financial Officer | 6.3yrs | US$6.09m | 0.76% $ 5.6m | |
| COO & Director | 1.3yrs | US$5.29m | 0.48% $ 3.5m | |
| Chief Accounting & Compliance Officer | 6.3yrs | US$5.50m | 0.39% $ 2.8m | |
| VP & Head of Clinical Operations | 7.1yrs | 데이터 없음 | 데이터 없음 | |
| Chief Medical Officer of Urology | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Clinical Development Advisor | no data | 데이터 없음 | 데이터 없음 | |
| Consultant | 9.1yrs | 데이터 없음 | 데이터 없음 |
6.3yrs
평균 재임 기간
63yo
평균 나이
경험이 풍부한 관리: RLMD의 경영진은 노련하고 경험이 풍부합니다(평균 재임 6.3 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | 14.1yrs | US$8.89m | 1.24% $ 9.1m | |
| Chief Financial Officer | 6.3yrs | US$6.09m | 0.76% $ 5.6m | |
| COO & Director | 10.5yrs | US$5.29m | 0.48% $ 3.5m | |
| Independent Chairman of the Board | 10.8yrs | US$854.29k | 데이터 없음 | |
| Member of Scientific Advisory Board | 8.9yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 3.3yrs | US$788.17k | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 6.4yrs | US$783.85k | 데이터 없음 | |
| Member of Scientific Advisory Board | 6.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 6.3yrs | 데이터 없음 | 데이터 없음 | |
| Chairman of Clinical Advisory Board | 1.1yrs | 데이터 없음 | 데이터 없음 |
6.4yrs
평균 재임 기간
63yo
평균 나이
경험이 풍부한 이사회: RLMD의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.4 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/20 19:35 |
| 종가 | 2026/05/20 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Relmada Therapeutics, Inc.는 10명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Maxim Jacobs | Edison Investment Research |
| Farzin Haque | Jefferies LLC |
| Andrew Berens | Leerink Partners LLC |